Avalo Therapeutics (AVTX) Profit After Tax (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Profit After Tax data on file, last reported at -$19.7 million in Q1 2026.

• Quarterly Profit After Tax fell 49.85% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.9 million (down 216.22% YoY) and the FY2025 annual result came in at -$78.3 million, down 122.89% from the prior year.
• Profit After Tax declined to -$19.7 million in Q1 2026, from -$13.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $98.5 million in Q2 2024 to a low of -$121.3 million in Q1 2024.
• A 5-year average of -$12.1 million and a median of -$13.0 million in 2022 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 1301.79% in 2024, down 1118.38% in 2024.
• Tracing AVTX's Profit After Tax over 5 years: stood at -$9.8 million in 2022, then grew by 16.75% to -$8.2 million in 2023, then sank by 332.65% to -$35.3 million in 2024, then surged by 60.94% to -$13.8 million in 2025, then plunged by 42.76% to -$19.7 million in 2026.
• The last three Profit After Tax figures came in at -$19.7 million (Q1 2026), -$13.8 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.